Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621841 | 0.78 | TSHR (0.47) | TSHRALDH1A1CYP3A4LMNAMAPT | |
| SCHEMBL28669648 | 0.77 | ALDH1A1 (0.59) | TSHRALDH1A1CYP3A4LMNAMAPT | |
| SCHEMBL4624018 | 0.77 | TSHR (0.59) | TSHRALDH1A1CYP3A4LMNAHTT | |
| SCHEMBL3970619 | 0.74 | ALDH1A1 (0.72) | TSHRALDH1A1CYP3A4LMNAMAPT | |
| SCHEMBL30613684 | 0.74 | MMP2 (0.64) | TSHRALDH1A1CYP3A4LMNAPOLB | |
| SCHEMBL21751533 | 0.74 | MMP2 (0.64) | TSHRALDH1A1CYP3A4LMNAPOLB | |
| SCHEMBL21751532 | 0.74 | MMP2 (0.64) | TSHRALDH1A1CYP3A4LMNAPOLB | |
| SCHEMBL8068632 | 0.74 | MMP2 (0.64) | TSHRALDH1A1CYP3A4LMNAPOLB | |
| SCHEMBL16057391 | 0.73 | TSHR (0.61) | TSHRALDH1A1CYP3A4LMNAHTT | |
| SCHEMBL17481681 | 0.73 | TSHR (0.61) | TSHRALDH1A1CYP3A4LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120031-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF (US) | 2010-05-13 | — | — | US | claimed |
| US-9156778-B2 | Cross-coupled peptide nucleic acids for detection of nucleic acids of pathogens | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-13 | — | — | US | disclosed |
| US-20120322053-A1 | CROSS-COUPLED PEPTIDE NUCLEIC ACIDS FOR DETECTION OF NUCLEIC ACIDS OF PATHOGENS | APPELLA DANIEL H (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120107794-A1 | Cross-Coupled Peptide Nucleic Acids for Detection of Nucleic Acids of Pathogens | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-03 | — | — | US | disclosed |
| US-20100120031-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120031-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2008039367-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039367-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120031-A1 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE | TERF2, TERF2IP, TCOF1 | TSHR 1482/4885ALDH1A1 4707/4885CYP3A4 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.